Navigation Links
Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results
Date:10/14/2008

l is currently expected to occur in early 2009.

"Fiscal 2008 was a year of progress at Alfacell," said Lawrence A. Kenyon, Alfacell's president. "We achieved a number of important objectives, including the U.S. license agreement with Strativa and completion of the Phase IIIb clinical trial for ONCONASE in UMM. In fiscal 2009, we plan to complete the NDA submission after receiving input from the FDA and to move forward with an expanded ONCONASE clinical development program."

About ONCONASE(R)

ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

Alfacell has licensed the U.S. commercial rights for ONCONASE to Strativa Pharmaceuticals, a division of Par Pharmaceutical, Inc. Strategic marketing and distribution agreements for ONCONASE have been secured with Megapharm Ltd. for Israel, BL&H Co. Ltd. for Korea, Taiwan and Hong Kong, USP Pharma Spolka Z.O.O., an affiliate of US Pharmacia, for Eastern Europe, and GENESIS Pharma, S.A. for Southeastern Europe.

ONCONASE has been granted fast track status and orphan-drug designation for the treatment of malignant mesothelioma by the FDA. Additionally, ONCONASE has been granted orphan-drug designation in the European Union and Australia.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threaten
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
2. Alfacell Hires Advisors to Advance Strategic Alternatives
3. Alfacell Receives NASDAQ Delisting Letter
4. Alfacell Receives NASDAQ Non-Compliance Notification
5. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
6. Alfacell Announces Retirement of Chief Executive Officer
7. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
8. Alfacell to Host Fiscal Second Quarter 2008 Financial Results Conference Call and Webcast
9. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
10. Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29
11. Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2014)... July 26, 2014 Canada Endoscopy ... market data on the Canada Endoscopy Visualization Systems ... US dollars, volume (in units) and average prices ... Endoscopy Visualization Systems, Mid-Range Endoscopy Visualization Systems and ... at http://www.marketresearchreports.biz/analysis/213254 . , The report also ...
(Date:7/25/2014)... 2014 "Ischemic Stroke and Cerebral ... data on the Ischemic Stroke and Cerebral Stroke ... and data relating to the clinical trials on ... global Ischemic Stroke Research Report 2014 at: ... the trial numbers and their recruitment status as ...
(Date:7/25/2014)... , July 25, 2014 Amgen (NASDAQ: ... today declared a $0.61 per share dividend for the ... on Sept. 5, 2014, to all stockholders of record ... 2014.  About Amgen Amgen is committed ... from serious illnesses by discovering, developing, manufacturing and delivering ...
(Date:7/25/2014)... MA -- Trillions of bacteria live in each person,s ... help digest food and stave off harmful infections, but ... , To help shed light on the role of ... associate professor Eric Alm recently tracked fluctuations in the ... year. The findings, described in the July 25 issue ...
Breaking Biology Technology:Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3
... AquaSensors , a Milwaukee-area company that makes ... a $360,000 investment from local angel group Silicon Pastures. ... which various sensors for water, waste-water, food, beverages, chemicals, ... to a standard "stick" device that converts the signals ...
... Before the calendar turns to a new year, here ... in 2005. Take it easy on the professor if ... ,Innovation: A minus. Wisconsin continues to produce more than ... such as the Wisconsin Alumni Research Foundation (WARF) and ...
... and financing of health care in the United States are ... , About one in seven Americans (15.7 percent) lack health ... According to the latest federal figures, health spending accounts for ... $1.68 trillion in 2003 works out to $5,670 for each ...
Cached Biology Technology:Grading Wisconsins high-growth economy 2Grading Wisconsins high-growth economy 3Health care economics make definition of 'cost' problems difficult 2Health care economics make definition of 'cost' problems difficult 3
(Date:7/25/2014)... an unknown interaction between microorganisms and salt. When ... of salt water and is left to dry, bacteria ... 3D morphologically complex formations, where they hibernate. Afterwards, simply ... was made by chance with a home microscope, but ... journal and may help to find signs of life ...
(Date:7/24/2014)... 24, 2014 /PRNewswire-iReach/ -- The Geneva Healthcare Suite, an ... has cut emergency room wait times by an average ... Medical Center, according to a recent study published in ... are using the suite to access data from incoming ... "Using Geneva,s technology platform we have been ...
(Date:7/24/2014)... that characterize sustainable university and college programs designed ... teachers. Specifically, one or more faculty members who ... with institutional motivation and commitment can ensure that ... Math (STEM) teacher shortages are especially acute in ... institutions seeking to increase the number of STEM ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3Creating sustainable STEM teacher preparation programs 2
... to humane alternatives to the use of animals in research ... requires using animals as part of the testing, what do ... Responsible Medicine, you invent your own test. , PCRM president ... world's first cruelty-free insulin assay, a test used to measure ...
... devices intended to optimize the cardiac function of patients ... patients might be at higher risk of dying suddenly ... Medical Center. , Besides maintaining optimal electrical stimulation to ... devices are giving cardiologists a new view of subtle ...
... It seems survival of the fittest affect every organism ... resistant than non-migratory ones to parasite infections; scientists just ... quite don't make it while migrating long distances, so ... , A little-studied outcome of animal migration is ...
Cached Biology News:PCRM develops world's first cruelty-free insulin assay 2Implanted Devices Detect High-Risk Heart Failure Patients 2Implanted Devices Detect High-Risk Heart Failure Patients 3
KNP-1 (HES1) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 35, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
Request Info...
Form: Ready to use Applications: Immunohistology-frozen, Immunohistology-paraffin, Western Blot, ELISA...
... H): 17 3/4" x 8 ... Programmable 0 - 100 hoursControl: Programmable 30 ... 40 user programmable protocols 3 operating modes ... temperature ramp-up from 37 - 95C and ...
Biology Products: